Case presentation: A 69-year-old
|
|
- Phebe Fowler
- 5 years ago
- Views:
Transcription
1 CLINICIAN UPDATE Prevention of Venous Thromboembolism in Total Knee and Hip Replacement David Warwick, MD, FRCS, FRCS(Orth) Case presentation: A 69-year-old woman had a cemented hip replacement 15 years previously, which initially fared well but then gradually failed because of aseptic loosening. She developed pain in her hip and was scheduled for a revision total hip replacement. A formal venous thromboembolism (VTE) risk assessment was undertaken before surgery according to the Hospital s policy for all orthopedic admissions. The risk assessment identified 2 conflicting issues. First, the patient had a particularly high risk of VTE, having had an above-knee deep vein thrombosis after her primary hip replacement and now required a major surgery, namely a revision hip arthroplasty. Second, she had a greater than usual risk of bleeding after surgery because of her obesity and the need for a large soft-tissue exposure, long-term aspirin, and supplementary bone graft from her iliac crest. The surgeon was faced with a common orthopedic problem, providing effective VTE prophylaxis without causing an equally important problem of surgical bleeding. Introduction Hip and knee replacement operations are now commonly performed, around 1 million annually in the United States and about the same number in Europe. These procedures are among the most successful and life-changing interventions available. However, the release of thromboplastins from dissected soft tissue and especially reamed bone, as well as venous stasis both during surgery and during relative postoperative immobility, provoke a high rate of thromboembolism. Several measures reduce the risk of VTE, but orthopedic surgeons are intuitively and properly concerned about the potential hemorrhagic side effect of pharmacological prophylaxis, which is associated with prolonged recovery, wound failure, and even periprosthetic infection. 1 After all, following the Hippocratic principle of primum non nocere, the most thrombosceptic surgeons have even argued that whereas a thombosis is an act of God, bleeding is caused by a surgeon. Who is to say that a symptomatic leg thrombosis is any more important than a symptomatic wound bleed or that a fatal embolism is more important than a fatal cerebral or retroperitoneal bleed? Studies of all-cause mortality in orthopedics have shown no clear change in mortality rates with or without prophylaxis. 2 The symptomatic nonfatal VTE rate of around 3% to 4% without prophylaxis may be no different from the increased rate of bleeding induced by pharmacological prophylaxis. A balanced approach, individualized for each patient, is therefore required to secure the safest outcome. Available Options and Evidence There are many consensus statements and meta-analyses, a few of which we cite General It is likely that early mobilization, careful surgical technique, and adequate rehydration will all reduce the risk of VTE after joint arthroplasty. Mechanical Graduated compression stockings are of some benefit but must be well fitted. Mechanical foot or calf compressors are effective as well in total hip arthroplasty and total knee arthroplasty, although probably not quite as effective as the best pharmacological methods. They have the drawbacks of impracticality and lack of compliance, espe- From the Department of Orthopaedic Surgery, University of Southampton, Southampton, United Kingdom. Correspondence to David Warwick, MD, Orthopaedic Surgery, University of Southampton, Southampton, United Kingdom SO16 6UY. davidwarwick@me.com (Circulation. 2012;125: ) 2012 American Heart Association, Inc. Circulation is available at DOI: /CIRCULATIONAHA
2 2152 Circulation May 1, 2012 Table 1. Drawbacks of Warfarin and Aspirin, Advantages of New Oral Agents Drawbacks of Warfarin Needs regular monitoring, which is expensive and time consuming If started too close to surgery or at too high a dose, there will be a risk of bleeding If started judiciously, later and at a lower dose, there will be an interval of several days during which the patient will be unprotected during his or her most thrombogenic phase Interaction with many drugs and alcohol Probably not as effective as LMWH Drawbacks of Aspirin Only weak antithrombotic effect so limited efficacy Evidence base controversial GI bleeding, wound bleeding Controversial professional support. Not recommended by NICE or ACCP, but recommended by first AAOS guidelines. Caution advised in 2011 AAOS guidelines. Not licensed for thromboprophylaxis Advantages of new oral agents At least as effective as enoxaparin Comparable bleeding profile No drug interactions No monitoring Can be used for out-of-hospital prophylaxis Less prone to HIT than LMWH Disadvantages of new oral agents Poor reversibility Caution in certain groups (eg, renal impairment) Only recently available, no long-term experience (vs LMWH) LMWH indicates low molecular-weight heparin; NICE, National Institute for Health and Clinical Excellence; ACCP, American College of Chest Physicians; AAOS, American Academy of Orthopaedic Surgeons; and HIT, heparin induced thrombocytopaenia. cially once the patient starts to mobilize. They also tend to be quite expensive. They have the advantage of freedom from hemorrhagic side effects, which appeals to the surgeon s intuition. Neuraxial Anesthesia Neuraxial anesthesia reduces VTE in arthroplasty and also reduces overall mortality. 9 However, the anesthetist will need to consider whether the insertion of a spinal or epidural catheter may be compromised by the risk of a neuraxial bleed when an anticoagulant is given concomitantly. Meticulous timing and adherence to published anesthetic guidelines is essential. Older Oral Agents Aspirin and warfarin (Coumadin) are widely used in North America, although warfarin is now generally regarded as obsolete in Europe. Aspirin is controversial (Table 1). Injectable Agents Low molecular-weight heparin has become the standard on the basis of 2 decades of clinical experience and a large number of well conducted studies. There is good evidence that, used carefully, low molecular-weight heparin is effective and does not carry an unacceptable bleeding risk. Fondaparinux (pentasaccharide) is also very effective in reducing VTE but carries, as do all pharmacological agents, a risk of bleeding side effects. 10 New Oral Agents The past 3 years have seen the advent of new oral agents, anti Xa or direct thrombin inhibitors. The anti Xa agent rivaroxaban is available in the United States for VTE prophylaxis in total hip arthroplasty and total knee arthroplasty. In Europe, the direct thrombin inhibitor dabigatran and the anti Xa agent apixaban are now also approved for hip and knee arthroplasty. 11,12 The data suggest that the thromboprophylactic efficacy and bleeding risk of these new agents is at least equivalent to the clinical trial comparator, enoxaparin. There are no direct comparisons between these new oral agents to test relative differences in efficacy or bleeding. These drugs have the important advantage over injectable agents of oral administration, which allows practical administration for a longer duration, especially after hospital discharge. They have the further advantage over existing oral agents relative to efficacy (aspirin), as well as avoidance of monitoring and potential drug interactions (warfarin). They are likely to change the way that prophylaxis is administered in orthopedic patients, in particular meeting the previously unmet need for pragmatic out-of-hospital prophylaxis. The various pharmacological options are summarized in Table 2. There may be discrepancies between the official manufacturer s product information, based on clinical trial programs, and the pragmatic and considered protocols advised by professional guidelines. These discrepancies are an underlying theme of this article. When to Start, When to Finish The thrombotic process starts as soon as the arthroplasty starts, and so thromboprophylaxis must be started as close to surgery as possible. 13 Pharmacological prophylaxis can be started before surgery, but if too close there will be a risk of bleeding; if too far before surgery, the drug effect will have decayed before the thrombotic process commences. Preoperative administration is also compromised because an unexpected delay in surgery or an earlier than expected procedure will exacerbate these problems. Postoperative administration is therefore more reliable with regard to a precise time for com-
3 Warwick Prevention of VTE in THR and TKR 2153 Table 2. Pharmaceutical Options in Total Hip Arthroplasty and Total Knee Arthroplasty Generic Name Brand Name Class Manufacturer Route Timing Frequency Enoxaparin Lovenox (US) LMWH Sanofi-Aventis sc Postop 12 hours Twice daily Enoxaparin Clexane (Europe) LMWH Sanofi-Aventis sc Preop 12 hours Once daily Dalteparin Fragmin LMWH Pfizer Inc/Eisai Inc sc Preop Once daily Tinzeparin (not yet licensed Innohep LMWH Leo Pharmaceuticals sc Preop Once daily in US; approved in Europe) Fondaparinux Arixtra Pentasaccharide GlaxoSmithKline sc 6 8 hours postop Once daily Warfarin Coumadin Jantoven Vitamin K antagonist Bristol-Myers-Squibb po variable Once daily Upsher-Smith Apixaban (not yet licensed Eliquis Anti-Xa Bristol-Myers Squibb/Pfizer po hours postop Twice daily in US; approved in Europe) Rivaroxaban Xarelto Anti-Xa Bayer po Postop 8 hours Once daily Dabigatran (not yet licensed in US; approved in Europe) Pradaxa Direct thrombin inhibitor Boeringher Ingelheim po Postop 1 4 hours Once daily This is a guide only. Any drug on this table should only be prescribed after confirmation by the prescribing physician of all data on dose, duration, indications, and contra-indications. For duration of administration, refer to both professional guidelines and manufacturer s product information. LMWH indicates low molecular-weight heparin; sc, by injection; postop, after surgery; preop, before surgery; and po, by mouth. mencement, but there is still a balance between giving the drug too soon (and risking bleeding) and too late (and risking thrombosis) (Figure 1). The duration of risk of VTE must also be considered. The risk after knee replacement is around 2 weeks and for hip replacement 4 to 6 weeks. 14 The risk may be longer in some individuals with extra risk factors. Prophylaxis should be continued until the risk has diminished (Figure 2). Because joint replacement patients only remain in hospital for a few days, prophylaxis must be extended beyond hospital discharge. This raises practical issues which can be readily addressed with an effective oral agent. Injectable agents and mechanical devices are less practical after hospital discharge. Guidelines Prophylaxis in the United States and Europe is now usually determined by hospital policy informed by guidelines. Guidelines distill the evidence and provide a reasoned and balanced practical summary for the surgeon. 15 Regular application of guidelines should help facilitate the implementation of prophylaxis. Despite a similar evidence base, guidelines vary. 16 The American Academy of Orthopaedic Surgeons 5 prefers pulmonary embolism as an end point and, with a paucity of studies providing this end point, cannot make firm recommendations on the basis of comparative studies. The first version in 2007 tended toward aspirin and warfarin postoperatively; the latest 2011 iteration 17 recommends the avoidance of aspirin before surgery and recommends postoperative pharmacological methods or mechanical methods for hip and knee arthroplasty. Those with a higher risk of thrombosis should have both; those with a higher risk of bleeding should have mechanical methods. Other guidelines, such as those of the American College of Chest Physicians 4 and the International Consensus Statement 8 are based on a venographic surrogate; this approach supports much firmer recommendations because there are a large number of studies with adequate sample size and significant differences in proportions between randomized groups. New iterations of each are due in The United Kingdom National Institute for Clinical Excellence guidelines 6 are a little less prescriptive, allowing some flexibility in timing of administration and combinations of mechanical and chemical methods. Figure 1. Just-in-time prophylaxis. A Balanced Approach It is generally held that hip and knee replacement have a risk of VTE high
4 2154 Circulation May 1, 2012 Figure 2. Discrepancy between duration of prophylaxis and onset of symptomatic VTE. VTE indicates venous thromboembolism. Reproduced with permission and copyright of the British Editorial Society of Bone and Joint Surgery. 14 enough to justify universal prophylaxis. However, the type of prophylaxis, the time of initiation, and the duration of administration are a matter for the clinician to judge, balancing the risk of thrombosis and of bleeding. Further, cost effectiveness is an increasingly relevant issue in financially constrained health economies. Mechanical Pharmaceutical Combinations To minimize bleeding risk yet maximize efficacy of VTE prophylaxis, mechanical and chemical methods are combined to exploit the advantages of each and avoid the disadvantages. A mechanical device is used on the contralateral leg during surgery, then on both legs as soon as the operation is finished. It is continued for as long as it is tolerated. A drug is started postoperatively, but only when the bleeding risk has diminished. If the patient has a higher than usual risk of VTE (for example, a past history of VTE, a family history of VTE, intercurrent malignancy, or predicted prolonged immobility), then a higher risk of bleeding with pharmacological prophylaxis might be accepted. The drug may be started closer to surgery and continued for longer. Furthermore, additional mechanical methods can be added to augment and maximize prophylaxis. The patient is encouraged and cajoled to tolerate the mechanical device for as long as possible. If the patient has a higher than usual risk of bleeding (for example, higher body mass, history of bleeding diathesis, or enlarged surgical incision for revision surgery), then a slightly higher risk of VTE might be accepted, which would indicate starting an anticoagulant later and covering the interim with an effective mechanical method. The Solution in this Case The surgeon weighed the conflicting risks of bleeding and VTE. Because the patient had a higher risk of bleeding, it was decided to delay the pharmacological prophylaxis until the day after surgery. Mechanical prophylaxis was instituted as early as possible. The patient was given well-fitting graduated compression stockings on arrival in hospital and was encouraged to wear these for 6 weeks. In the operating room, mechanical foot compressors were applied to the opposite leg and activated throughout the procedure. At the end of the procedure, the foot compressor was applied to the operated leg as well. Compression was continued until the patient started to mobilize. The device was then removed only when the patient was tentatively mobilizing but was reattached by the nurse or physiotherapist immediately afterward. By the fifth day, the patient was mobilizing well and was discharged. It was deemed impractical to use the device at home. A new oral agent (Rivaroxaban 10 mg once daily) was given at 9:00 AM on the day after surgery. This delay was judged sensible to bring the drug close enough to surgery for prophylactic effect but to allow adequate hemostasis. The drug was prescribed for 5 weeks. The patient developed no hematoma and no symptomatic VTE. Disclosures Dr Warwick has received honoraria and traveling expenses from Boehringer Ingelheim (manufacturers of Dabigatran, a direct thrombin inhibitor) for 2 lectures in 2011 and 1 in The author received traveling expenses for his contribution to the International Consensus Statement Editorial Board in References 1. Parvizi J. Does excessive anticoagulation predispose to peri-prosthetic infection? Arthroplasty. 2007;22: Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Rel Res. 2008;466: Sachdeva A, Dalton M, Amaragiri SV, Lees T. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2010: CD Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:381S 453S. 5. Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P III, Haralson RH III, Watters WC III. American Academy of Orthopaedic Surgeons clinical practice guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am. 2009:-91: NICE Clinical Guideline 92 (2010): reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital Available at byid&o Accessed October 27, Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Reddy DJ. Combined intermittent pneumatic compression and pharmacological prophylaxis for prevention of venous thromboembolism in high risk patients (a review.) Cochrane Database Syst Rev. 2008:CD Nicolaides AN, Breddin HK, Carpenter P, Coccheri S, Conard J, De Stefano V, Elkoofy
5 Warwick Prevention of VTE in THR and TKR 2155 N, Gerotziafas G, Guermazi S, Haas S, Hull R, Kalodiki E, Kristof V, Michiels JJ, Myers K, Pineo G, Prandoni P, Romeo G, Samama MM, Simonian S, Xenophonthos S. Prevention and treatment of venous thromboembolism: International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006;25: Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, Baigent C. Towards evidence based guidelines for the prevention of venous thromboembolism: systematic review of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess. 2005;49: Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162: Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363: Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375: Warwick D, Roschensher N. The critical thrombosis period in major orthopedic surgery: when to start and when to stop prophylaxis. Clin Appl Thromb Hemost. 2010;16: Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, FitzGerald G, Turibio FM. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events. J Bone Joint Surg. 2007;89B: Warwick DJ, Dahl OE, Fisher WD. Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br. 2008;90: Eikelboom JW. American Academy of Orthopaedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest. 2009;135: Preventing venous thromboembolic disease in patients underoing elective hip and knee arthroplasty: evidence-based guideline and evidencereport. guidelines/vte/vte_full_guideline.pdf. Accessed November 19, 2011.
VTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationVenous thromboembolism after total knee replacement or total hip replacement: what can be learnt from root-cause analysis?
TRAUMA AND ORTHOPAEDIC SURGERY Ann R Coll Surg Engl 2016; 98: 538 542 doi 10.1308/rcsann.2016.0202 Venous thromboembolism after total knee replacement or total hip replacement: what can be learnt from
More informationVenous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
Winner of the AAHKS Award Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials Greg A. Brown, MD, PhD The Journal of Arthroplasty Vol. 24
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationFactor Xa Inhibition in the Management of Venous Thromboembolism: Important Safety Information. Important Safety Information (cont d)
Factor Xa Inhibition in the Management of Venous Thromboembolism: The Role of Fondaparinux WARNING: SPINAL/EPIDURAL HEMATOMAS Epidural or spinal hematomas may occur in patients who are anticoagulated with
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationWhat evidence exists that describes the efficacy of mechanical prophylaxis for venous thromboembolism (VTE) in adult surgical patients?
July 2015 Rapid Review Evidence Summary McGill University Health Centre: Division of Nursing Research and MUHC Libraries What evidence exists that describes the efficacy of mechanical prophylaxis for venous
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationProtocol. Postsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Postsurgical Outpatient Use of Limb Compression Devices for (10128) (Formerly Outpatient Use of Limb Pneumatic Compression Devices for ) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/15
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationPage: 1 of 13. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Last Review Status/Date: March 2014 Page: 1 of 13 Compression Devices for Venous Description Patients undergoing major orthopedic surgery are at increased risk for venous thromboembolism (VTE). Patients
More informationAdam Goldfarb, M.A., D.C., D.E.S.S. Introduction
Venous Thromboembolism Prophylaxis following Lower Extremity Orthopedic Surgery: A Review of the Biomedical Research Literature and Evidence-Based Policy in the United States. Adam Goldfarb, M.A., D.C.,
More informationPostsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Clinical Position Statement Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Effective: October 2017 Next Review: September 2018 CLINICAL POSITION STATEMENT Postsurgical
More informationFINDINGS FROM THE GLOBAL ORTHOPAEDIC REGISTRY
Arthroplasty Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events FINDINGS FROM THE GLOBAL ORTHOPAEDIC
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationEffect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention
European Heart Journal Supplements (2008) 10 (Supplement C), C8 C13 doi:10.1093/eurheartj/sun004 Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationProphylaxis for Venous Thromboembolism Following Total Knee Arthroplasty: A Survey of Korean Knee Surgeons
Original Article Knee Surg Relat Res 2016;28(3):207-212 http://dx.doi.org/10.5792/ksrr.2016.28.3.207 pissn 2234-0726 eissn 2234-2451 Knee Surgery & Related Research Prophylaxis for Venous Thromboembolism
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationTITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms DATE: 23 August 2011 CONTEXT AND POLICY ISSUES: Thromboembolism occurs when a blood
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationINDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY
INDICATIONS FOR THROMBO-PROPHYLAXIS AND WHEN TO STOP ANTICOAGULATION BEFORE ELECTIVE SURGERY N.E. Pearce INTRODUCTION Preventable death Cause of morbidity and mortality Risk factors Pulmonary embolism
More informationUW MEDICINE PATIENT EDUCATION. Treating Blood Clots. What is a blood clot? DRAFT
UW MEDICINE PATIENT EDUCATION Treating Blood Clots About deep vein thrombosis (DVT) and pulmonary embolism (PE) and how they are treated This handout explains blood clots, their symptoms, and how they
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationPage: 1 of 14. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Subject: Post-Surgical Outpatient Use of Limb Page: 1 of 14 Last Review Status/Date: March 2015 Post-Surgical Outpatient Use of Limb Compression Devices for Venous Description Patients undergoing major
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationThese are guidelines only and can be deviated from if it is thought to be in the patient s best interest.
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all
More information1/27/2016. Disclosure. Goals. The Risk and Prevention of Venous Thromboembolism (VTE) in Patients With Foot and Ankle Pathology
The Risk and Prevention of Venous Thromboembolism (VTE) in Patients With Foot and Ankle Pathology STEVEN STEINLAUF, MD THE ORTHOPAEDIC FOOT AND ANKLE INSTITUTE OF SOUTH FLORIDA CLINICAL ASSISTANT PROFESSOR
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationPrimary VTE Thromboprophylaxis
Primary VTE Thromboprophylaxis Controversies in Hematology 53 rd Annual Meeting of Thai Society of Hematology Bundarika Suwanawiboon, MD Division of Hematology Department of Medicine Faculty of Medicine
More informationVenous Thromboembolism Prophylaxis
I CSI Health Care Guideline: Venous Thromboembolism Prophylaxis I NSTITUTE FOR CLINICAL S YSTEMS IMPROVEMENT Eighth Edition September 2011 The information contained in this ICSI Health Care Guideline is
More informationPRIMARY TOTAL KNEE & HIP
Clinical Guideline Version 2.0 Title: PRIMARY TOTAL KNEE & HIP Venous ThromboEmbolic (VTE) Guideline Target Audience: thopedic Surgeons and their Advanced Practice Practitioner partners; Hospitalists,
More informationResearch Article. Abstract
Research Article Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty Harpreet Bawa, MD Jack W. Weick, MD Douglas R. Dirschl, MD Hue H. Luu, MD
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationNational Institute for Health and Clinical Excellence Health Technology Appraisal
National Institute for Health and Clinical Excellence Health Technology Appraisal Rivaroxaban for the prevention of venous thromboembolism after elective orthopaedic surgery of the lower limbs Comment
More informationAspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty: The EPCAT II Trial Wednesday, June 6, 2018, 2:00PM ET Guest Author: David R. Anderson, MD Presenter: Sara Vazquez, PharmD Moderators:
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationPradaxa (dabigatran)
Pradaxa (dabigatran) Policy Number: 5.01.574 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Pradaxa
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationTechnology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245
Apixaban for the prevention ention of venous thromboembolism after total hip or knee replacement in adults Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta245 NICE 2018.
More informationDisclosures. Venous Thromboembolism Prophylaxis: What every orthopaedic surgeon needs to know. Published Guidelines
Venous Thromboembolism Prophylaxis: What every orthopaedic surgeon needs to know Paul F. Lachiewicz, MD Chapel Hill Orthopedic Surgery & Sports Medicine Consulting Professor Duke Orthopaedic Surgery Disclosures
More informationVenous Thromboembolism Prophylaxis
I CSI Health Care Guideline: Venous Thromboembolism Prophylaxis I NSTITUTE FOR CLINICAL S YSTEMS IMPROVEMENT Seventh Edition August 2010 The information contained in this ICSI Health Care Guideline is
More informationAbbreviations: ACCP American College of Chest Physicians; CI confidence interval; CPMP Committee for Proprietary Medicinal Products
Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points* Alexander G.G. Turpie, MD; Kenneth A. Bauer, MD; Bengt
More informationDeep vein thrombosis: diagnosis, prevention and treatment
Deep vein thrombosis: diagnosis, prevention and treatment Catherine Bagot BSc, MD, MRCP, FRCPath and Campbell Tait BSc, FRCP, FRCPath Deep vein thrombosis can lead to significant morbidity and has well-recognised
More informationDeep venous thrombosis and pulmonary embolism in joint replacement surgery
Deep venous thrombosis and pulmonary embolism in joint replacement surgery Even though joint replacement surgery is an effective procedure and in expert hands yields a low complication rate, deep venous
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationJAMES PAGET HEALTHCARE NHS TRUST
CLINICAL GUIDELINE FOR REGIONAL ANAESTHESIA AND THE USE OF LOW MOLECULAR WEIGHT HEPARINS (LMWH) IN THE PERIOPERATIVE PERIOD 1. INTRODUCTION LMWH have been proven to be effective in reducing the risk of
More informationHospital Acquired VTE: update on national guidance
Hospital Acquired VTE: update on national guidance Rebecca Chanda Consultant Pharmacist - Thrombosis and Haemostasis Guy s and St Thomas Hospitals NHS Foundation Trust Chair of the UK Clinical Pharmacy
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationUpdate on the risk of DVT during air travel - does the economy class syndrome really exist?
Update on the risk of DVT during air travel - does the economy class syndrome really exist? Thomas HW Stadlbauer Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationBest Practice for Deep Vein Thrombosis Prevention: A Research Review. Pamela Dusseau Carly Macklin Natalie Russell Danielle Williams
Running Head: BEST PRACTICE FOR DEEP VEIN THOMBOSIS PREVENTION 1 Best Practice for Deep Vein Thrombosis Prevention: A Research Review Pamela Dusseau Carly Macklin Natalie Russell Danielle Williams Ferris
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationTHROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY. Title of Guideline. (Governance) Version Number 1 Date of Review October 17
Title of Guideline THROMBOPROPHYLAXIS IN ORTHOPAEDIC SURGERY Contact Name and Job Title (Author) Gary Masterman Deputy Chief Pharmacist (Governance) Division & Specialty Specialist Services Guideline Number
More informationThe compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery
DOI 10.1186/s40064-016-2724-1 RESEARCH The compliance of thromboprophylaxis affects the risk of venous thromboembolism in patients undergoing hip fracture surgery Yuan Gao 1, Anhua Long 2,3, Zongyan Xie
More informationDeep Vein Thrombosis
Deep Vein Thrombosis from NHS (UK) guidelines Introduction Deep vein thrombosis (DVT) is a blood clot in one of the deep veins in the body. Blood clots that develop in a vein are also known as venous thrombosis.
More informationVenous Thromboembolism Prophylaxis
I CSI Health Care Guideline: Venous Thromboembolism Prophylaxis I NSTITUTE FOR CLINICAL S YSTEMS IMPROVEMENT Fourth Edition June/2007 The information contained in this ICSI Health Care Guideline is intended
More informationSUBJECT: LIMB PNEUMATIC COMPRESSION EFFECTIVE DATE: 06/27/13 DEVICES FOR VENOUS REVISED DATE: 06/26/14 THROMBOEMBOLISM PROPHYLAXIS
MEDICAL POLICY SUBJECT: LIMB PNEUMATIC COMPRESSION PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical
More informationVenous Thromboembolism Following Major Orthopedic Surgery: What is the Risk After Discharge? Orthopedics
Orthopedics REVIEW ARTICLE Venous Thromboembolism Following Major Orthopedic Surgery: What is the Risk After Discharge? Juan I. Arcelus, MD, PhD; Joseph A. Caprini, MD, MS; James C. Kudrna, MD, PhD Orthopedics
More information*Corresponding Author:
Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra
More informationCopyright Restricted. Orthopedic surgery carries a high risk of venous
Practice Patterns in the Use of Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty Insights From the Multinational Global Orthopaedic Registry (GLORY) Richard J. Friedman, MD, FRCSC, Alexander
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationLovenox to xarelto The Borg System is 100 % Retrievable & Reusable Lovenox to xarelto
Lovenox to xarelto The Borg System is 100 % Lovenox to xarelto Background: I got a DVT in my left calf after my fifth knee surgery. I'm a 32yo healthy, competitive athlete and have never had any healthy
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationReducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge
Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge What is a venous thromboembolism (VTE)? This is a medical term that describes a blood clot that develops in a deep vein
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationMeasure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) 2013 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 4.3 NQF-ENORSE VOLUNTARY CONSENSUS STANARS FOR HOSPITAL CARE Measure Information Form Measure Set: Venous Thromboembolism (VTE) Set Measure Set I #: Performance Measure Name: Intensive
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More information